A major announcement from global pharmaceutical leader Eli Lilly and Company, which has confirmed plans to build a new $6.5 billion manufacturing facility in the Houston area. The Indianapolis-based company selected the location Generation Park, a 4,300-acre business district approximately 20 miles northeast of downtown Houston, and will represent the largest manufacturing campus of its kind in the United States part of Lilly’s broader strategy to increase domestic medicine production.
After evaluating more than 300 proposals across 40 states, Eli Lilly selected Houston based on its robust infrastructure, access to utilities and transportation, strong talent pool, and the presence of the world’s largest medical center. Port Houston’s international connectivity also played a key role in the decision.
Economic Impact and Job Creation
The development is expected to have a significant impact on both the local and state economy. Lilly will create approximately 615 permanent jobs in Houston, including roles for engineers, scientists, and lab technicians, with average annual salaries exceeding $100,000. In addition, construction of the one-million-square-foot facility is projected to generate around 4,000 temporary jobs.
The company has secured 236 acres within Generation Park for the project and will collaborate with local universities and colleges to develop a skilled workforce pipeline to support long-term operations.
State Incentives and Support
Texas Governor Greg Abbott confirmed that the project has been awarded $5.5 million from the Texas Enterprise Fund, with additional incentives approved through the Jobs, Energy, Technology, and Innovation Act. Governor Abbott described the initiative as “one of the largest pharmaceutical manufacturing investments in our nation’s history,” noting its role in strengthening Texas’s life sciences sector and advancing healthcare innovation.
Next-Generation Manufacturing
The Houston facility will integrate artificial intelligence and advanced technologies to support next-generation drug production. Among its priorities will be the large-scale manufacturing of orforglipron, Eli Lilly’s first oral medication designed to treat obesity and type 2 diabetes. The drug is expected to be submitted for regulatory approval by the end of the year.
This new campus is part of Eli Lilly’s broader $50 billion plan to expand its U.S. manufacturing footprint. Recent investments include a $5 billion facility in Virginia and a manufacturing site in North Carolina, with two additional U.S. projects to be announced later this year.
Long-Term Vision
Eli Lilly’s investment underscores a strategic shift to strengthen domestic production capacity, reduce reliance on overseas suppliers, and accelerate delivery timelines for critical medicines. According to company estimates, every dollar invested in the Houston project will generate up to $4 in local economic activity.
Freeway Group Inc. recognizes the importance of projects like this not only for the pharmaceutical industry but also for the broader economy, workforce development, and healthcare innovation. Houston’s selection demonstrates the city’s growing role as a hub for life sciences and advanced manufacturing.
